OUR PEOPLE

There’s no typical GLCC employee. We come from a wide range of backgrounds and bring our own unique strengths.
But what we do have in common is our shared value for altruism through our journey in clinical research.

Our team consists of project managers, clinical research associates, regulatory affairs specialists, and administrators who work with our management team in a supportive and collaborative environment.

CAROLINE ALSWEILER

DIRECTOR CLINICAL RESEARCH

BSc, PGDipHSc, MHSc, CCRA

As an accomplished pharmaceutical professional with experience ranging from Head of Clinical Operations, Project Manager, Senior Clinical Research Scientist, and Data Manager, Caroline has a broad depth of knowledge which covers many aspects of the industry. She is highly skilled in clinical development, business strategy and interpersonal relations. Caroline maintains accreditation with the Association of Clinical Research Professionals (US).

An important part of her leadership role includes educating all levels of clinical research professionals in New Zealand.

Caroline started her career in clinical research at Guy’s Hospital, London. After a number of years, in early 2004 she returned to New Zealand where she continued her clinical research career. At this time, she became a member of the New Zealand Association of Clinical Research (NZACRes) Executive Committee.

As part of her professional development pathway, Caroline currently sits as a Steering Committee Member for ANZACT, the Australian and New Zealand Alliance for Cardiovascular Trials network. This network has been established to provide a framework to support the development and conduct of investigator-initiated high quality, multi-centre clinical trials and associated research activities. Due to her extensive clinical research experience, Caroline was elected as a member of The University of Auckland Human Participants Ethics Committee. Caroline’s strong ties with academic leadership extends to Australia with membership of the Australian Cardiovascular Alliance and the US attendance on multiple global clinical operations management teams overseeing multinational trials.

PROFESSOR HARVEY WHITE

DIRECTOR

MB ChB DSc FRACP FACC FESC FAHA FHKCC (Hon) FCSANZ FRSNZ

In the late 1980s, Harvey along with a close-knit team of clinical research specialists working at world-renowned Green Lane Hospital founded GLCC. Their aim was to improve the health and quality of life of people throughout the world with innovative clinical research. Harvey has led the organization through these past three decades in his role as clinical director which has seen huge advances in cardiovascular care over this period.

Harvey trained at Green Lane Hospital, Auckland and at Harvard and Brigham and Women’s Hospital, Boston, USA. In 2008, he attended a World Medical Association INSEAD Leadership Course, Fontainebleau, Paris, France.

In recognition of his work on brinolysis and end systolic volumes as prognostic factors, he was awarded a DSc by Otago University, Dunedin, New Zealand. He was awarded the 1998 Prince Mahidol Award for Medicine by the King of Thailand for introducing brinolytic therapy in many developing countries, including China. He is a Matai (Chief) in Samoa and has a “pou” in the Te Awamutu Walk of Fame. He has been the NZ Chairman and the President of the combined Australian and NZ Cardiac Society.

His citation for the NZ Royal Society states ‘for advocacy on behalf of patients’. He has advocated retaining the name ‘Patient’. He is an Advocate for more Automated External defibrillators (AEDs) and has a trust “Start a heart” for promoting greater number of AEDs.

He has been Chairman of the Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM), Hirulog Early Reperfusion Occulsion (HERO) and Stabilisation of Atherosclerotic Plaque by Initiation of darapLadib Therapy (STABILITY) Trials. He is currently Co-chairman of the Redefinition of Myocardial Infarction European Society of Cardiology /American College of Cardiology /American Heart Association Consensus group and along with colleagues de ned the 5 types of heart attacks.